Unknown

Dataset Information

0

Structural insights into the mechanisms and specificities of IgG-active endoglycosidases.


ABSTRACT: The conserved N-glycan on Asn297 of immunoglobulin G (IgG) has significant impacts on antibody effector functions, and is a frequent target for antibody engineering. Chemoenzymatic synthesis has emerged as a strategy for producing antibodies with homogenous glycosylation and improved effector functions. Central to this strategy is the use of enzymes with activity on the Asn297 glycan. EndoS and EndoS2, produced by Streptococcus pyogenes, are endoglycosidases with remarkable specificity for Asn297 glycosylation, making them ideal tools for chemoenzymatic synthesis. Although both enzymes are specific for IgG, EndoS2 recognizes a wider range of glycans than EndoS. Recent progress has been made in understanding the structural basis for their activities on antibodies. In this review, we examine the molecular mechanism of glycosidic bond cleavage by these enzymes and how specific point mutations convert them into glycosynthases. We also discuss the structural basis for differences in the glycan repertoire that IgG-active endoglycosidases recognize, which focuses on the structure of the loops within the glycoside hydrolase (GH) domain. Finally, we discuss the important contributions of carbohydrate binding modules (CBMs) to endoglycosidase activity, and how CBMs work in concert with GH domains to produce optimal activity on IgG.

SUBMITTER: Du JJ 

PROVIDER: S-EPMC7476101 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural insights into the mechanisms and specificities of IgG-active endoglycosidases.

Du Jonathan J JJ   Klontz Erik H EH   Guerin Marcelo E ME   Trastoy Beatriz B   Sundberg Eric J EJ  

Glycobiology 20200301 4


The conserved N-glycan on Asn297 of immunoglobulin G (IgG) has significant impacts on antibody effector functions, and is a frequent target for antibody engineering. Chemoenzymatic synthesis has emerged as a strategy for producing antibodies with homogenous glycosylation and improved effector functions. Central to this strategy is the use of enzymes with activity on the Asn297 glycan. EndoS and EndoS2, produced by Streptococcus pyogenes, are endoglycosidases with remarkable specificity for Asn29  ...[more]

Similar Datasets

| S-EPMC5069557 | biostudies-literature
| S-EPMC1783469 | biostudies-literature
| S-EPMC3793210 | biostudies-literature
| EMPIAR-10435 | biostudies-other
| EMPIAR-10458 | biostudies-other
| S-EPMC4059211 | biostudies-literature
| S-EPMC5806680 | biostudies-literature
| S-EPMC7153993 | biostudies-literature
| S-EPMC3953293 | biostudies-literature
| S-EPMC7022352 | biostudies-literature